In vivo administration of cytokine in allogeneic bone marrow chimeras.
When we analyzed the in vivo efficacy of cytokine administration in murine allogeneic bone marrow chimeras, mitogen-induced responses to ConA, PHA, LPS, or PWM were increased by the in vivo administration of human recombinant granulocyte colony-stimulating factor (rG-CSF), human recombinant interleukin 2 (rIL-2), or WEHI-3B conditioned medium (CM). Furthermore, we found increased alloreactive mixed lymphocyte reactions (MLRs) against donor and/or host type alloantigens in spleen cells from (BALB/c----C3H/He) chimeras, although cytotoxic activity against BALB/c or C3H/He target cells was not detected in spleen cells from these chimeras. Since no significant increase of T cells or Ia positive cells was observed, some functional activation, rather than changes in the cell count, appeared to relate to increase immunoreactivity. An increased IL-2 production in spleen cells from chimeras injected with cytokine was observed shortly after the cessation of cytokine administration. Thereafter, an IL-2 production in these chimeras decreased around 45 days after bone marrow transplantation and then recovered nearly to the control level. An increased IL-2 responsiveness was also observed in spleen cells from these chimeras. These findings suggest that the in vivo administration of rG-CSF as well as rIL-2 or WEHI-3B CM (IL-3) can modulate the immunoreactivity in chimeras via the network of immune systems.
Imamura
M
M
Third Department of Internal Medicine, Hokkaido University School of Medicine, Sapporo, Japan.
Fujimoto
H
H
Hashino
S
S
Fukuhara
T
T
Kobayashi
M
M
Kasai
M
M
Sakurada
K
K
Miyazaki
T
T
D000818:Animals; D000954:Antigens, Surface / Q000032:analysis; D001685:Biological Factors / Q000494:pharmacology*; D016026:Bone Marrow Transplantation / Q000276:immunology*; D002678:Chimera / Q000276:immunology; D003115:Colony-Stimulating Factors / Q000494:pharmacology; D003470:Culture Media; D016207:Cytokines; D003602:Cytotoxicity, Immunologic; D006086:Graft vs Host Disease / Q000276:immunology; D016179:Granulocyte Colony-Stimulating Factor; D007376:Interleukin-2 / Q000096:biosynthesis / Q000494:pharmacology; D007377:Interleukin-3 / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D008810:Mice, Inbred C57BL; D011994:Recombinant Proteins / Q000494:pharmacology; D013154:Spleen / Q000276:immunology
D000954:Antigens, Surface; D001685:Biological Factors; D003115:Colony-Stimulating Factors; D003470:Culture Media; D016207:Cytokines; D007376:Interleukin-2; D007377:Interleukin-3; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor